MIV tests SagaX' embolic protection technology
This article was originally published in Clinica
MIV Therapeutics is beginning animal trials of an embolic protection device for catching blood clots that become dislodged during cardiac procedures and can travel to the brain and cause a stroke. The aortic embolic protection device (AEPD) was developed by SagaX Medical Technologies, a company recently acquired by MIV (see Clinica No 1150, p 14). The AEPD, which is placed in a main artery, is designed for use during invasive heart procedures such as electrophysiology, valve dilatations and valve repair through angioplasty. The technology may also find broad preventative application during minimally invasive alternatives to open surgery, said Vancouver, British Columbia-based MIV, which estimates the product's market to exceed $1.5-1.8bn by 2009.